Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Nouri vs REMEVi

Nouri
Graded #455

Lower grade

vs+15.600000000000009
REMEVi
Graded #108

Higher grade

The verdict

REMEVi takes it — 70.4/100 to 54.8/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueREMEVi +9
45
54
Dose & formulationREMEVi +24
40
64
Clinical oversightREMEVi +22
64
86
Labs & monitoringREMEVi +12
53
65
FulfillmentREMEVi +10
87
97
Contract termsREMEVi +14
55
69
Nouri · left barREMEVi · right bar

The numbers

MetricNouriREMEVi
WeighScore54.8/10070.4/100
GradeCC
Scorecard rank#455#108
SemaglutideNot disclosed$199/mo (starting dose, compounded)
TirzepatideNot disclosed$269/mo (starting dose, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Nouri

Graded #455 · C

Strengths

  • Named clinical MSO partner (Wasef Health, PC; Michael Wasef, MD) with public contact email
  • Named 503A compounding pharmacy partner (Jungle Jim's Pharmacy, Fairfield OH) with full address
  • Available in all 50 states per the FAQ
  • Flat per-dose pricing within each tier — no dose-escalation surcharge
  • Nutrition and movement coaching included in the medication price

Where it loses points

  • Compounded medications only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
  • Operating entity name not disclosed in the Terms of Service
  • Terms 'where we operate' language is slightly weaker than the FAQ's all-50-states claim
  • Video visit required in some states, but those states aren't listed
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
REMEVi

Graded #108 · C

Strengths

  • The first bilingual GLP-1 clinic — care delivered in English and Spanish by clinicians trained in both, not auto-translated
  • Compounded semaglutide from $199/mo and tirzepatide from $269/mo on the 52-week plan, with the same price every month (no titration price hikes)
  • LegitScript-certified and licensed in all 50 states + DC, with an NPI-verified pharmacy and overnight shipping
  • Transparent all-inclusive pricing with no hidden fees and cancel anytime; full legal suite (Privacy, Terms, HIPAA, Refund)

Where it loses points

  • Lowest pricing requires a 52-week commitment — month-to-month is higher ($279 semaglutide / $339 tirzepatide)
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy or Zepbound
  • The specific compounding pharmacy is not named (described as 'NPI-verified')
  • A newer, patient-founded clinic; press mentions (Fortune, AP, Reuters) are syndicated PR, not editorial endorsements

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard